• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Stage II Seminoma: Why Chemotherapy Should Remain a Standard.II期精原细胞瘤:为何化疗应维持为标准治疗方案。
Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.
2
Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.腹膜后淋巴结清扫术治疗睾丸精原细胞瘤:基于人群的实践和生存结局。
World J Urol. 2018 Jan;36(1):73-78. doi: 10.1007/s00345-017-2099-0. Epub 2017 Oct 12.
3
Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.腹膜后淋巴结清扫术和切除术治疗睾丸癌:最佳实践的最新进展。
Ther Adv Urol. 2012 Aug;4(4):187-205. doi: 10.1177/1756287212443170.
4
Clinical Stage IIA-IIC Seminoma: Radiation Therapy versus Systemic Chemotherapy versus Retroperitoneal Lymph Node Dissection.临床 IIA 期-IIC 期精原细胞瘤:放疗与全身化疗与腹膜后淋巴结清扫的比较。
Oncol Res Treat. 2018;41(6):360-363. doi: 10.1159/000489408. Epub 2018 May 16.
5
Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.睾丸癌的原发和化疗后腹膜后淋巴结切除术。
Oncol Res Treat. 2018;41(6):370-378. doi: 10.1159/000489508. Epub 2018 May 17.
6
[Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].改良腹膜后淋巴结清扫术治疗睾丸非精原细胞性生殖细胞肿瘤的疗效
Ai Zheng. 2008 Dec;27(12):1302-6.
7
Two cycles of cisplatin-based chemotherapy for low-volume stage II seminoma: results of a retrospective, single-center case series.低容量 II 期精原细胞瘤行两个周期顺铂为基础的化疗:回顾性单中心病例系列研究结果。
Chemotherapy. 2012;58(5):405-10. doi: 10.1159/000345701. Epub 2013 Jan 3.
8
Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.睾丸精原细胞瘤晚期疾病的管理。14例报告及文献复习。
Arch Ital Urol Androl. 2002 Jun;74(2):81-5.
9
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.临床Ⅰ期非精原细胞瘤生殖细胞肿瘤患者接受 1 周期辅助博来霉素、依托泊苷和顺铂治疗与原发腹膜后淋巴结清扫术后的晚期毒性和复发情况 - 一项 III 期试验队列的 13 年随访分析。
Eur J Cancer. 2021 Sep;155:64-72. doi: 10.1016/j.ejca.2021.06.022. Epub 2021 Aug 6.
10
Testicular cancer.睾丸癌
Curr Probl Cancer. 1998 Jul-Aug;22(4):187-274. doi: 10.1016/s0147-0272(98)90012-5.

引用本文的文献

1
Diagnosis and therapy of recurrent renal metastases after surgery for testicular seminoma: a rare case report and review of the literature.睾丸精原细胞瘤术后复发性肾转移瘤的诊断与治疗:1例罕见病例报告并文献复习
Front Oncol. 2025 May 22;15:1542368. doi: 10.3389/fonc.2025.1542368. eCollection 2025.
2
Iodine‑125 seeds combined with carboplatin in the treatment of retroperitoneal metastatic seminoma: A case report and literature review.碘-125粒子联合卡铂治疗腹膜后转移性精原细胞瘤:1例报告并文献复习
Oncol Lett. 2024 Feb 15;27(4):156. doi: 10.3892/ol.2024.14289. eCollection 2024 Apr.
3
Stage II Seminoma: Is There Something New on the Horizon?II期精原细胞瘤:未来会有新进展吗?
Eur Urol Open Sci. 2023 Jan 30;49:78-79. doi: 10.1016/j.euros.2023.01.007. eCollection 2023 Mar.

本文引用的文献

1
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.GETUG SEMITEP 试验:基于氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对预后良好的精原细胞瘤进行化疗降级。
Eur Urol. 2022 Aug;82(2):172-179. doi: 10.1016/j.eururo.2022.04.031. Epub 2022 May 20.
2
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.睾丸精原细胞瘤和非精原细胞瘤:ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Apr;33(4):362-375. doi: 10.1016/j.annonc.2022.01.002. Epub 2022 Jan 19.
3
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.预测转移性非精原细胞瘤生殖细胞肿瘤(NSGCT)男性患者的结局:国际生殖细胞肿瘤协作组更新联盟的结果。
J Clin Oncol. 2021 May 10;39(14):1563-1574. doi: 10.1200/JCO.20.03296. Epub 2021 Apr 6.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Clinical utility of plasma miR-371a-3p in germ cell tumors.血浆 miR-371a-3p 在生殖细胞肿瘤中的临床应用价值。
J Cell Mol Med. 2019 Feb;23(2):1128-1136. doi: 10.1111/jcmm.14013. Epub 2018 Dec 7.
6
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.北美睾丸癌幸存者接受现代顺铂化疗后不良健康结局的多机构评估
J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.
7
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes.临床 IIA 期和 IIB 期精原细胞瘤的放疗或化疗:患者结局的系统评价和荟萃分析。
Ann Oncol. 2015 Apr;26(4):657-668. doi: 10.1093/annonc/mdu447. Epub 2014 Sep 11.
8
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.顺铂和依托泊苷联合或不联合异环磷酰胺治疗转移性精原细胞瘤的风险适应性研究:GETUG S99 多中心前瞻性研究结果。
Eur Urol. 2014 Feb;65(2):381-6. doi: 10.1016/j.eururo.2013.09.004. Epub 2013 Sep 13.
9
Stage II testicular seminoma: patterns of recurrence and outcome of treatment.II期睾丸精原细胞瘤:复发模式与治疗结果
Eur Urol. 2004 Jun;45(6):754-59; discussion 759-60. doi: 10.1016/j.eururo.2004.01.020.

II期精原细胞瘤:为何化疗应维持为标准治疗方案。

Stage II Seminoma: Why Chemotherapy Should Remain a Standard.

作者信息

Naoun Natacha, Bernard-Tessier Alice, Fizazi Karim

机构信息

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.

出版信息

Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.

DOI:10.1016/j.euros.2022.06.010
PMID:36793752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9922911/
Abstract

Chemotherapy (three cycles of bleomycin + etoposide + cisplatin or four of etoposide + cisplatin) cures the vast majority of stage II seminomas. Retroperitoneal lymph node dissection (RPLND) is safe in early-stage seminoma, but the risk of relapse is not negligible. Long-term chemotherapy side effects are a reality but may be reduced using de-escalation strategies such as in the SEMITEP trial design, motivated by growing interest in survivorship. RPLND may be an option for well-informed select patients who understand that it may be associated with a higher rate of relapse than with cisplatin-based chemotherapy. In any case, local and systemic treatment should not be performed outside high-volume centers.

摘要

化疗(博来霉素+依托泊苷+顺铂三个周期或依托泊苷+顺铂四个周期)可治愈绝大多数II期精原细胞瘤。腹膜后淋巴结清扫术(RPLND)在早期精原细胞瘤中是安全的,但复发风险并非可以忽略不计。长期化疗副作用是现实存在的,但可以通过采用降阶梯策略来降低,比如在SEMITEP试验设计中,这是出于对生存质量关注度的不断提高。对于充分知情且理解RPLND可能比基于顺铂的化疗有更高复发率的特定患者,RPLND可能是一种选择。无论如何,局部和全身治疗不应在非高容量中心进行。